Dr. Schenk on the Importance of Investigating Novel Targets in Lung Cancer
Erin Schenk, MD, PhD, discusses the importance of investigating novel targets and pathways in lung cancer.
EP: 1.Dr. Gandara on Developments in HER2-Targeted Therapies in NSCLC
EP: 2.Dr. Gainor on the Potential Value of Targeting TROP-2 and CEACAM5 in Lung Cancer
EP: 3.Dr. Santos on the Potential Role for CEACAM5- and KEAP1-Targeted Therapies in NSCLC
EP: 4.Dr. Schenk on the Importance of Investigating Novel Targets in Lung Cancer
EP: 5.Dr. Skoulidis on the Rationale to Target TROP2 in Lung Cancer
Erin Schenk, MD, PhD, assistant professor of medicine, Division of Medical Oncology, University of Colorado School of Medicine, medical oncologist, University of Colorado Medicine, discusses the importance of investigating novel targets and pathways in lung cancer.
The list of novel targets being evaluated in lung cancer is rapidly expanding, Schenk says. Moreover, as the field develops a greater understanding of disease biology and resistance mechanisms in lung cancer, novel pathways become relevant options for targeted therapy. Moreover, emerging novel targets inform clinical trial designs, Schenk adds.
Currently, emerging targets, such as TROP2, KEAP1, HER3, IL-2, SHP2, and TGF-β, have informed potentially novel options for treating patients with lung cancer or overcoming resistance to some of the therapies that are currently available, Schenk concludes.
